Inclusion Criteria:

- Men and women age 18 and older

- Patients who are able and willing to give consent and able to attend all study visits

- Patients who are suffering from symptoms of bone metastases or multiple myeloma bone
lesions:

- Patients who have received radiation without adequate relief from metastatic bone
pain as determined by the patient and treating physician

- those for whom their treating physician would not prescribe radiation or additional
radiation treatments

- patients who refuse additional radiation therapy.

- Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication

- Targeted bone/tumor interface are ExAblate device accessible and are located in ribs,
extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the
following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)

- Targeted bone/tumor interface (most painful lesion) size up to 55 cm2 in surface area

- Patient whose targeted (treated) lesion is on bone and the interface between the bone
and lesion is deeper than 10-mm from the skin.

- Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS
device accessible

- Able to communicate sensations during the ExAblate treatment

- Patients on ongoing chemotherapy regimen at the time of eligibility:

1. with same chemotherapy regime (as documented from patient medical dossier), And

2. Worst pain NRS still ≥ 4 And

3. do NOT plan to initiate a new chemotherapy for pain palliation should be
eligible for the study.

Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.

- No radiation therapy to targeted (most painful) lesion in the past two weeks
Bisphosphonate intake should remain stable throughout the study duration.

- Patients will have from 1 to 5 painful lesions and only the most painful lesion will
be treated.

- Patients with persistent distinguishable pain associated with 1 site to be treated
(if patient has pain from additional sites, the pain from the additional sites must
be evaluated as being less intense by at least 2 points on the NRS compared to the
site to be treated).

Exclusion Criteria:

- Patients who either

- Need surgical stabilization of the affected bony structure (>7 fracture risk score,
see Section 7.4) OR

- Targeted tumor is at an impending fracture site (>7 on fracture risk score, see
Section 7.4).

OR

- Patients with surgical stabilization of tumor site with metallic hardware

- More than 5 painful lesions, or more than 1 requiring immediate localized treatment

- Targeted (treated) tumor is in the skull

- Patients on dialysis

- Patients with life expectancy < 3-Months

- Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected
to hinder them from completing this study.

- Patients with unstable cardiac status including:

- Unstable angina pectoris on medication

- Patients with documented myocardial infarction within six months of protocol entry

- Congestive heart failure requiring medication (other than diuretic)

- Patients on anti-arrhythmic drugs

- Severe hypertension (diastolic BP > 100 on medication)

- Patients with standard contraindications for MR imaging such as non-MRI compatible
implanted metallic devices including cardiac pacemakers, size limitations, etc.

- Patients with an active infection or severe hematological, neurological, or other
uncontrolled disease.

- Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or
Magnevist) including advanced kidney disease

- KPS Score < 60 (See "Definitions" below)

- Severe cerebrovascular disease (multiple CVA or CVA within 6 months)

- Individuals who are not able or willing to tolerate the required prolonged stationary
position during treatment (approximately 2 hrs.)

- Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.

- Are participating or have participated in another clinical trial in the last 30 days

- Patients initiating a new chemotherapy regime for pain purposes only, or radiation
(for the targeted most painful lesion) within the last 2 weeks Note: Planned multiple
courses of chemotherapy are not considered New Chemotherapy.

- Patients unable to communicate with the investigator and staff.

- Patients with persistent undistinguishable pain (pain source unidentifiable of the
targeted lesion)

- Patient whose bone-lesion interface is < 10-mm from the skin

- Targeted (most painful) tumor NOT visible by non-contrast MRI,

- Targeted (most painful) tumor Not accessible to ExAblate

- The targeted tumor is less than 2 points more painful compared to other painful
lesions on the site specific NRS.